Solventum's Q3: Strong Performance & Raised Guidance
Update: 2025-11-08
Description
Solventum, a healthcare solutions provider, reported robust Q3 2025 results, surpassing Wall Streets expectations with revenue of $2.1 billion and non-GAAP profit per share of $1.50. Adjusted EBITDA reached $497.5 million, and operating margin soared to 80.6%, up from 13.2% in Q3 2024. The company attributed these gains to its three-phase transformation plan, focusing on commercial restructuring, supply chain improvements, and product innovation. Solventum raised its full-year adjusted earnings per share guidance to $5.96, driven by commercial momentum, supply chain savings, and a new initiative called Transform for the Future. The company plans to reinvest cost savings into R&D and commercial infrastructure, ensuring sustained growth despite tariff pressures.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
